CS21192A3 - Complex containing precipitation factor ix - Google Patents

Complex containing precipitation factor ix

Info

Publication number
CS21192A3
CS21192A3 CS92211A CS21192A CS21192A3 CS 21192 A3 CS21192 A3 CS 21192A3 CS 92211 A CS92211 A CS 92211A CS 21192 A CS21192 A CS 21192A CS 21192 A3 CS21192 A3 CS 21192A3
Authority
CS
Czechoslovakia
Prior art keywords
factor
complex containing
containing precipitation
precipitation factor
vitamin
Prior art date
Application number
CS92211A
Other languages
English (en)
Inventor
Yendra Dr Linnau
Maria Dipl Ing Sazgary
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of CS21192A3 publication Critical patent/CS21192A3/cs
Publication of CZ280297B6 publication Critical patent/CZ280297B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
  • Medicinal Preparation (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CS92211A 1991-01-25 1992-01-24 Komplex obsahující srážecí faktor IX CZ280297B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0016391A AT402261B (de) 1991-01-25 1991-01-25 Komplex enthaltend den gerinnungsfaktor ix

Publications (2)

Publication Number Publication Date
CS21192A3 true CS21192A3 (en) 1992-08-12
CZ280297B6 CZ280297B6 (cs) 1995-12-13

Family

ID=3483232

Country Status (12)

Country Link
US (2) US5281661A (cs)
EP (1) EP0496725B1 (cs)
JP (2) JP2651307B2 (cs)
AT (2) AT402261B (cs)
CA (1) CA2059979C (cs)
CZ (2) CZ280297B6 (cs)
DE (1) DE59207638D1 (cs)
DK (1) DK0496725T3 (cs)
ES (1) ES2098485T3 (cs)
FI (1) FI100111B (cs)
HU (1) HU212362B (cs)
SK (2) SK280130B6 (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231401T2 (de) 1991-03-01 2001-02-08 Rhone-Poulenc Rorer International (Holdings) Inc., Greenville Herstellung von faktor-ix
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
DE69523722T2 (de) 1994-06-30 2002-08-01 Dade Behring Inc., Deerfield Bioaktive poröse trennteile
US5888826A (en) * 1994-06-30 1999-03-30 Dade Behring Inc. Combination reagent holding and test device
US5602037A (en) * 1994-06-30 1997-02-11 Dade International, Inc. Combination reagent holding and test device
DE19506633A1 (de) * 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5958716A (en) * 1996-06-06 1999-09-28 Dade Behring Inc. Blood factor assay
CA2308610A1 (en) * 1997-11-05 1999-05-14 Welfide Corporation Heparin cofactor ii preparation and process therefor
WO2005033140A1 (ja) * 2003-09-30 2005-04-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 高純度血液凝固ｉｘ因子調製物およびその精製方法
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
EP2360171A1 (en) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
TWI445714B (zh) 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
US20120076779A1 (en) 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
WO2012154272A1 (en) 2011-02-25 2012-11-15 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
WO2025068923A2 (en) 2023-09-26 2025-04-03 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2543448A1 (fr) * 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4721572A (en) * 1985-07-12 1988-01-26 Miles Laboratories, Inc. Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
ATE130620T1 (de) * 1986-01-06 1995-12-15 Blood Systems Inc Therapeutisches blutprodukt, mittel und verfahren zu dessen erzeugung.
JPS63108000A (ja) * 1986-05-15 1988-05-12 Green Cross Corp:The 第８因子の精製方法
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
DE3914869C1 (cs) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De

Also Published As

Publication number Publication date
SK280989B6 (sk) 2000-10-09
JP2651307B2 (ja) 1997-09-10
JPH08259449A (ja) 1996-10-08
FI920342L (fi) 1992-07-26
AT402261B (de) 1997-03-25
FI100111B (fi) 1997-09-30
HUT63863A (en) 1993-10-28
CZ280725B6 (cs) 1996-04-17
DK0496725T3 (da) 1997-06-09
ATE146220T1 (de) 1996-12-15
EP0496725A3 (en) 1993-05-05
HU212362B (en) 1996-06-28
EP0496725A2 (de) 1992-07-29
CZ154794A3 (en) 1996-04-17
ES2098485T3 (es) 1997-05-01
JP2866047B2 (ja) 1999-03-08
HU9200225D0 (en) 1992-04-28
CA2059979A1 (en) 1992-07-26
SK280130B6 (sk) 1999-08-06
FI920342A0 (fi) 1992-01-24
US5409990A (en) 1995-04-25
EP0496725B1 (de) 1996-12-11
CA2059979C (en) 2003-04-15
DE59207638D1 (de) 1997-01-23
JPH04295432A (ja) 1992-10-20
US5281661A (en) 1994-01-25
ATA16391A (de) 1996-08-15
CZ280297B6 (cs) 1995-12-13

Similar Documents

Publication Publication Date Title
CS21192A3 (en) Complex containing precipitation factor ix
EP0727437A3 (en) PEG-protein adducts
SE8206168D0 (sv) Preparations and process for preparation thereof
IL120009A0 (en) Bacterial production of hydrophobic polypeptides
ES2000030A6 (es) Metodo de purificar factor sanguineo viii:c
FI931274A0 (fi) Menetelmä puhdistettujen glykolipidien valmistamiseksi käyttäen membraanierotusmenetelmää
AU5710186A (en) Method for selectively increasing the ratio of single major components of teicoplanin A2 complex
CA2178208A1 (en) Purification of vitamin-k dependent proteins by membrane chromatography
MY119366A (en) A process for the preparation of factor ix from biological sources
DK0719276T3 (da) Ïstradiolestre med stærk oral virkning samt farmaceutiske præparater med indhold deraf
TNSN86154A1 (fr) Procede pour la preparation de cefodizime
ES8706693A1 (es) Procedimiento para la produccion de derivados del acido 7-amino-3-alcoximetil-3-cefem-4-carboxilico
EG20136A (en) Process for the preparation of 5-chloro-3-chloro-2-thiophenecarloxylic acid esters
EP0776969A3 (de) Verfahren zur Herstellung von Proteinen durch kontrollierte proteolytische spaltung von Pro-Proteinen
ES8706688A1 (es) Procedimiento selectivo para la preparacion del isosorbido-5-mononitrato
HU913573D0 (en) Complexes containing s(+)alkaneacids and alpha-hydroxy-alkaneacids
AU3579589A (en) Process for producing concentrates from aqueous liquids
JPS5251089A (en) Method of immobilizing glutathione-synthetase and process of producing glutathione with the immobilized synthetase
AU6914991A (en) Solubilization of t-pa
FR2703262B1 (fr) Mélanges gazeux.
JPS6488366A (en) Iron colloid labeling antibody and preparation thereof and histocytochemical detection
AU5888086A (en) Process for separation, by precipitation, of the molybdenum contained in solutions of uranyl nitrate
JPS56117791A (en) Purification of kallikrein
MX9709657A (es) Preparacion de un polvo de proteina acilada.

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20020124